A Study of CD19/CD20 Dual CAR-T Cells in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma(B-NHL)
Latest Information Update: 16 Feb 2022
Price :
$35 *
At a glance
- Drugs YTS 101 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 29 Jan 2022 Planned initiation date changed from 10 Mar 2021 to 10 Mar 2022.
- 29 Jan 2022 Status changed from not yet recruiting to suspended.
- 08 Jan 2021 New trial record